Restoring the biological activity of crizanlizumab at physiological conditions through a pH-dependent aspartic acid isomerization reaction

In this study, we report the isomerization of an aspartic acid residue in the complementarity-determining region (CDR) of crizanlizumab as a major degradation pathway. The succinimide intermediate and iso-aspartic acid degradation products were successfully isolated by ion exchange chromatography fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bickel, Fabian, Griaud, François, Kern, Wolfram, Kroener, Frieder, Gritsch, Manuela, Dayer, Jérôme, Barteau, Samuel, Denefeld, Blandine, Kao-Scharf, Chi-Ya, Lang, Manuel, Slupska-Muanza, Izabela, Schmidt, Carla, Berg, Matthias, Sigg, Jürgen, Boado, Lina, Chelius, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762811/
https://www.ncbi.nlm.nih.gov/pubmed/36519228
http://dx.doi.org/10.1080/19420862.2022.2151075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762811/
https://www.ncbi.nlm.nih.gov/pubmed/36519228
http://dx.doi.org/10.1080/19420862.2022.2151075

Ejemplares similares